Adrenocortical carcinoma · 2023-506888-34-00
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- Authorised (EU CTIS)Approved to run; CTIS does not say whether it is recruiting — ask the site
- Phase
- Phase 1
- Sponsor
- BeOne Medicines AG
- Registry records
- CTIS 2023-506888-34-00 (Authorised)Registry last updated 2026-06-02
Eligibility, line by line
Not yet checkedThe eligibility text has not been analysed yet, so there is no grade. Read the criteria on the registry.
Full eligibility text as the registry publishes it
Routes in: how this trial is reached and paid for
Free patient navigation
myTomorrows (Amsterdam) provides medically trained, multilingual patient navigators who search ClinicalTrials.gov, EU CTIS and ISRCTN and can support a doctor through an expanded-access application. Free to patients and families.
A navigator keeps searching after any single page stops being current. Use it alongside this site, not instead of your oncologist.
Verify with: myTomorrows for patients
0
Sites (0)
The registry lists no sites. Countries: France.